Updates on Combination Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia
| Autor: | Eleanor K. Broadbent, Ellen C. Rubin, Karrine D. Brade, Alison L Blackman |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Combination therapy business.industry 030106 microbiology Salvage therapy biochemical phenomena metabolism and nutrition Fosfomycin bacterial infections and mycoses medicine.disease_cause medicine.disease Methicillin-resistant Staphylococcus aureus 03 medical and health sciences 0302 clinical medicine Infectious Diseases Staphylococcus aureus Internal medicine Bacteremia Medicine Vancomycin 030212 general & internal medicine Daptomycin business medicine.drug |
| Zdroj: | Current Infectious Disease Reports. 22 |
| ISSN: | 1534-3146 1523-3847 |
| DOI: | 10.1007/s11908-020-00737-8 |
| Popis: | Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with a large clinical burden and high rates of treatment failure with first-line treatment options. Literature for combination antimicrobial therapies for initial treatment or salvage therapy in the setting of persistent bacteremia is developing. Various combination strategies have emerged for the treatment of MRSA bacteremia, including vancomycin or daptomycin in combination with either anti-staphylococcal penicillins, early- and late-generation cephalosporins, ceftaroline, trimethoprim-sulfamethoxazole, or fosfomycin. When used as second-line or salvage therapy, evidence suggests use of these combinations shorten the duration of bacteremia. More recently, data have emerged evaluating this strategy for initial therapy, although results are conflicting. Use of combination therapy for MRSA bacteremia may shorten bacteremia duration, but the optimal combination, doses, timing of use, and exact impact on clinical outcomes are still evolving. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink